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Androgen receptor expression was analyzed in the
CWR22 human prostate cancer xenograft model to
better understand its role in prostate cancer recur-
rence after castration. In androgen-dependent tu-
mors, 98.5% of tumor cell nuclei expressed androgen
receptor with a mean optical density of 0.26  0.01.
On day 2 after castration androgen deprivation de-
creased immunostained cells to 2% that stained
weakly (mean optical density, 0.16  0.08). Cellular
proliferation measured using Ki-67 revealed <1% im-
munostained cells on day 6. Androgen receptor im-
munostained cells increased to 63% on day 6 and 84%
on day 32 although immunostaining remained weak.
Cellular proliferation was undetectable beyond day 6
after castration until multiple foci of 5 to 20 prolifer-
ating cells became apparent on day 120. These foci
expressed increased levels of prostate-specific anti-
gen, an androgen receptor-regulated gene product. In
tumors recurrent 150 days after castration androgen
receptor-immunostaining intensity was similar to
CWR22 tumors from intact mice although the percent-
age of cells immunostained was more variable. The
appearance of proliferating tumor cells that ex-
pressed androgen receptor and prostate-specific anti-
gen 120 days after castration suggests that these cells
represent the origin of recurrent tumors. (Am J
Pathol 2002, 160:219–226)
High-affinity binding of dihydrotestosterone to androgen
receptor (AR) causes AR to function as a transcription
factor1,2 that regulates a network of androgen response
genes.3,4 Prostate cancer (CaP) is androgen-dependent
and its growth is mediated by this AR-regulated gene
network. Androgen deprivation causes reduced AR ex-
pression,5 apoptosis, decreased cell volume,6 and de-
cline of serum prostate-specific antigen (PSA). However,
most CaPs eventually develop the capacity for recurrent
growth in the absence of testicular androgen. All of 22
specimens of testicular androgen-independent meta-
static CaP showed positive immunohistochemical stain-
ing for AR protein.7 Transurethral resection of prostate
specimens from 10 untreated CaP patients and 20 pa-
tients with CaP recurrent after androgen deprivation were
compared and no significant difference in the percent-
age of AR-positive cells was found.8,9 Because AR ex-
pression is similar in androgen-dependent and recurrent
CaP, we sought to understand how AR expression
changes in relation to cellular proliferation in the interval
between androgen deprivation and tumor recurrence.
CWR22 is an androgen-dependent human CaP xeno-
graft propagated subcutaneously in nude mice. CWR22
resembles the majority of human CaPs; CWR22 secretes
PSA, undergoes tumor regression after androgen depri-
vation, and recurs as a palpable, growing and ultimately
lethal tumor after several months in the absence of tes-
ticular androgen.10–13 We demonstrated that recurrence
of CWR22 tumor after androgen deprivation was associ-
ated with re-expression of a network of androgen-regu-
lated genes including PSA, human kallikrein-2, Nkx 3.1,
AR co-activator ARA-70, cell cycle genes Cdk1 and
Cdk2,3 and insulin-like growth factor binding protein-5.14
Recently, Amler and associates15 have reported incom-
plete reactivation of the androgen response pathway de-
spite androgen absence in recurrent CWR22 using mi-
croarray analysis. Similar expression of AR and these
androgen-regulated genes in androgen-dependent and
recurrent CWR22 tumors suggested a role for AR regu-
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lation of gene expression in the development of recurrent
CWR22 despite the absence of testicular androgen.
Video image analysis has been used to quantitate AR
expression more precisely than visual scoring.16–19 We
developed an automated method for measuring AR ex-
pression in individual cells that was used to demonstrate
the dependence of AR protein levels on serum androgen
levels in the CWR22 model.20 In CWR22 tumor-bearing
mice castrated for 6 days, AR mean optical density
(MOD) decreased to 57% of levels in tumors from intact
mice. After 72 hours of exogenous testosterone adminis-
tration to 6-day castrated mice, AR MOD in CWR22 re-
turned to the level found in tumors from intact mice.
Cellular proliferation of testosterone-treated tumors
reached 50% of the original androgen-stimulated
CWR22 tumors from intact mice.14 These data suggested
that the majority of CWR22 cells on day 6 after castration
had functional AR. In archived radical prostatectomy
specimens, AR protein content was higher in androgen-
dependent, clinically localized CaP and lower in prostate
intraepithelial neoplasia than benign prostatic hyperpla-
sia (BPH).19,20 AR immunostaining intensity was similar in
androgen-stimulated and recurrent tumors from the
CWR22 xenograft and transurethral resection of the pros-
tate specimens of BPH; all tissues were small volume and
fixed immediately after procurement.20 Finally, 12 speci-
mens of recurrent CaP and 16 specimens of BPH, all
acquired by transurethral resection of the prostate and
fixed immediately, exhibited similar AR immunostaining
(unpublished data). Taken together, these findings sug-
gest that AR is expressed in androgen-stimulated CaP,
diminished but recoverable after castration, and re-ex-
pressed despite androgen absence on CaP recurrence.
We sought to test the hypothesis that re-expression of
AR coincided with the onset of androgen-independent
cellular proliferation in CaP. To test this hypothesis, the
temporal relationship between AR protein expression and
cellular proliferation was determined using the CWR22
xenograft model during tumor regression and recurrence
after castration. Quantitative immunohistochemistry and
color video image analysis were used to measure pre-
cisely the proportion of cells expressing AR and Ki-67
and the intensity of expression of AR associated with




Nude/nude athymic mice were purchased from Harlan
Sprague-Dawley, Inc., Indianapolis, IN. The CWR22 tu-
mor model has been maintained by continuous passage
since December of 1995 from CWR22 cells that were a
gift from Thomas A. Pretlow, MD, PhD, Case Western
Reserve University). CWR22 tumors were transplanted as
1 million dissociated cells suspended in Matrigel (Collab-
orative Research Inc., Bedford, MA) injected subcutane-
ously into nude mice 4 to 5 weeks of age.11,12 A 12.5-mg
sustained-release testosterone pellet (Innovative Re-
search of America, Sarasota, FL) was placed subcutane-
ously in each animal 2 days before tumor injection and
every 3 months thereafter to maintain consistent serum
levels of testosterone of 4 ng/ml. After tumors reached
a volume of 1 cm3, animals were anesthetized with me-
thoxyflurane, castrated, and the testosterone pellets re-
moved. Intact mice bearing tumors and castrated ani-
mals with either regressed or recurrent CWR22 tumors
were exposed to methoxyflurane and sacrificed by cer-
vical dislocation. Tumor height, width, and depth were
measured using calipers and tumor volume was calcu-
lated by multiplying these three measurements and
0.5234. Tumors were excised and cut into several pieces
(125 mm3); half was frozen in liquid nitrogen and half
was fixed in 10% buffered formalin for 24 to 48 hours,
washed in phosphate-buffered saline (PBS) for 24 hours,
and paraffin-embedded. Specimens of BPH prepared
identically were used as positive controls. Blood was
obtained on sacrifice of all tumor-bearing mice for mea-
surement of serum PSA.
Immunohistochemistry
The avidin-biotin-immunoperoxidase technique21 was
modified for use in paraffin-embedded tissues that were
immunostained using capillary action with a MicroProbe
staining station (Fisher Scientific, Pittsburgh, PA).22
Monoclonal antibody (mAb) F39.4.1 (BioGenex, San
Ramon, CA) recognizes an epitope in the N-terminal
region of human AR.23 mAb MIB-1 (Oncogene, Cam-
bridge, MA) and polyclonal antibody MIB-5 (DAKO
Corp., Carpinteria, CA) react with the cell cycle-associ-
ated antigen Ki-67 expressed during the proliferative
phases (G1, S, G2, and M) but absent in the resting phase
(G0) of the cell cycle.
24 mAb A67-B/E3 (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) corresponds to amino
acids 1 to 261 representing full length PSA p30 of human
origin.25
Paraffin-embedded CWR22 tumor specimens were cut
into 6-m-thick histological sections. After deparaffiniza-
tion and rehydration, tissue sections were heated to
100°C for 30 minutes in a vegetable steamer in the pres-
ence of antigen retrieval solution (CITRA, pH 6.0; Bio-
Genex) and cooled for 10 minutes. Slides were preincu-
bated with 2% normal horse serum for 5 minutes at 37°C
and washed with automation buffer (Fisher Scientific).
AR mAb was diluted 1:300 (0.13 g/ml in PBS contain-
ing 0.1% bovine serum albumin, pH 7.4) and sections
were stained for 120 minutes at 37°C. Slides were incu-
bated in biotinylated anti-mouse immunoglobulin (IgG)
(Vector Laboratories, Inc., Burlingame, CA) for 15 min-
utes at 37°C (1:200 in PBS, pH 7.4) and in horseradish
peroxidase-conjugated avidin-biotin complex (Vector
Laboratories, Inc.) for 15 minutes at 37°C (1:100 in PBS,
pH 7.4). The immunoperoxidase complexes were visual-
ized using diaminobenzidine tetrahydrochloride (Vector
Laboratories, Inc) for 8 minutes at 37°C (0.75 mg/ml in
Tris buffer containing 0.03% hydrogen peroxide, pH 7.6).
Slides were dehydrated through graded alcohol solutions
and cleaned by Hemo-De xylene substitute (Fisher Sci-
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entific). Counterstaining was performed with hematoxylin
(Gill’s formula, 1:6 dilution; Fisher Scientific) for 12 sec-
onds. Slides were mounted with Permount and cover-
slips. Two representative slides were selected from each
time point and stained with the polyclonal AR antibodies,
AR52 and PG-21, following protocols reported previous-
ly.5,26 AR52 was provided by Dr. Elizabeth M. Wilson
(University of North Carolina at Chapel Hill) and PG-21
was provided by Dr. Gail S. Prins (University of Illinois at
Chicago). Slides prepared from a CWR22 tumor on day 6
after castration and human BPH were included as exter-
nal controls to avoid variation of immunostaining intensity
caused during staining procedures. Nonimmune mouse
IgG (Vector Laboratories, Inc.) was used instead of AR
mAb at the same IgG concentration for negative control
slides prepared from the same tissue blocks as speci-
mens; negative control slides were nonreactive.
MIB-1 mAb staining was performed at an IgG concen-
tration of 0.5 g/ml (1:50). All other steps were as de-
scribed for AR immunostaining. Serial sections adjacent
to the sections stained for AR were obtained from tumors
on day 120 after castration and stained with MIB-1 mAb.
Colon cancer tissue served as positive controls and 0.5
g/ml of nonimmune mouse IgG was used instead of
MIB-1 mAb at the same IgG concentration for negative
control slides prepared from the same tissue blocks as
specimens; negative control slides were nonreactive.
PSA mAb (1:50, 4 g/ml) was biotinylated and blocked
in vitro using the Iso-IHC kit (InnoGenex, San Ramon, CA)
to avoid background staining caused by infiltrated mu-
rine cells in CWR22 tumors harvested from castrated
animals. Sections were digested in Proteinase-K (20 g/
ml, DAKO Corp.) for 6 minutes at room temperature.
Sections were incubated in the blocking solution and
labeled with PSA mAb for 1 hour at 37°C and in strepta-
vidin-peroxidase (InnoGenex) for 5 minutes at 37°C. Im-
munoreaction was visualized by diaminobenzidine tetra-
hydrochloride for 8 minutes at 37°C. Double
immunohistochemistry was performed on additional
CWR22 slides to co-localize PSA expression among Ki-
67-positive tumor cells. Sections were eluted by glycine
buffer (pH 2.3) for 5 minutes three times at room temper-
ature and antigen-retrieved as described previously. A
mixture of normal goat serum (2%) and avidin (1:50 in
PBS, Vector Laboratories, Inc.) was used for blocking for
5 minutes at 37°C. Sections were reacted with MIB-5
(1:50, 20 g/ml) mixed with biotin (1:50 in PBS, Vector
Laboratories, Inc.) for 2 hours at 37°C. The same avidin-
biotin-peroxidase complex technique used for MIB-1 was
performed. Immunoreaction was visualized by 3-amino-
9-ethylcarbazole (AEC) (Vector Laboratories, Inc.) for 10
minutes at 37°C. BPH and CaP specimens were used as
positive controls. For the negative control slide, nonim-
mune rabbit IgG (Vector Laboratories, Inc.) was used
instead of PSA mAb at the same IgG concentration;
appropriate biotinylated IgGs were replaced with PBS in
PSA and MIB-5 steps to check against cross-reactions.
Negative control slides showed neither nonspecific reac-
tion nor cross-reactions.
Automated Digital Image Analysis
Automated digital image analysis was performed as de-
scribed previously.20 Briefly, imaging hardware con-
sisted of a Zeiss Axioskop microscope, a 3-chip charge-
coupled device camera (C5810; Hamamatsu Photonics
Inc., Hamamatsu, Japan), a camera control unit
(Hamamatsu Photonics Inc.), and a Pentium-based per-
sonal computer. Each field of view for AR-stained slides
was digitized at total magnification 1200 using a 40
objective (numerical aperture, 1.3). For MIB-1- and PSA-
stained slides, a 20 objective (numerical aperture, 0.6)
was used for total magnification at 600. Twenty images
that contained 200 to 250 nuclei at 1200 and 400 to
500 nuclei at 600 provided an adequate sample size for
each tumor because the deviation of average intensity
values of randomly chosen immunopositive areas be-
came stable (within 5%).
Immunopositivity and immunonegativity were deter-
mined using a linear discriminant analysis based on hue,
saturation, and intensity of 100 immunostained cells of an
intact CWR22 specimen and 100 cells of a negative
control slide, respectively. The positivity for AR, Ki-67,
and PSA was defined as the total number of pixels from
immunopositive areas divided by the total number of
pixels from all nuclear areas detected in a given speci-
men.
Differences in MOD and percentage of AR-, Ki-67-,
and PSA-positive cells from all images from all tumors at
various time points were evaluated using Wilcoxon rank
sum tests. Correlations between features were examined
using the Pearson’s product moment correlation test.
F-tests were performed to compare the variances among
samples. Statistical significance was achieved if P 
0.05.
Western Immunoblot Analysis of AR
Lysates were prepared from frozen CWR22 tumors. Tu-
mor tissue (100 mg) was pulverized in liquid nitrogen,
thawed on ice, and mixed with 1.0 ml of RIPA buffer with
protease inhibitors (PBS, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, 0.5 mmol/L
phenylmethylsulfonyl fluoride, 10 mol/L pepstatin, 4
mol/L aprotinin, 80 mol/L leupeptin, and 5 mmol/L
benzamidine). Tissue was homogenized on ice for 30
seconds using a Biohomogenizer (Biospec Products,
Inc., Bartlesville, OK). Two l of 0.2 mol/L phenylmethyl-
sulfonyl fluoride were added and homogenates incu-
bated 30 minutes on ice. Homogenates were centrifuged
at 10,000  g for 20 minutes; supernatants were col-
lected and centrifuged to prepare final lysates. Superna-
tant protein (100 g) from each sample was electropho-
resed in 12% sodium dodecyl sulfate-polyacrylamide
gels and electroblotting to Immobilon-P membrane (Mil-
lipore Corp., Bedford, MA). Immunodetection used AR
mAb F39.4.1 at 1:10,000 dilution. Secondary antibody
(goat anti-mouse IgG conjugated to horseradish peroxi-
dase; Amersham Corp., Arlington Heights, IL) was used
for detection by enhanced chemiluminescence (DuPont-
NEN Research Products, Boston, MA).
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Results
Average MOD and percentage of cells expressing AR
(percent AR positivity) were determined in tumors from
CWR22-bearing mice before and after castration (Table
1). The majority of nuclei in CWR22 tumors from intact
nude mice (98.5  0.2%) showed intense staining of AR
(MOD was 0.26  0.01) (Figure 1). On day 1 after cas-
tration, AR MOD decreased and remained low on day 4
after castration whereas AR percent positivity declined to
a minimum on day 2 (2%) and remained low on day 4
(10%). On day 6 after castration, AR-positive nuclei in-
creased sixfold to 63% and were distributed evenly
throughout all tumor sections. AR positivity increased
further to 71% on day 12. AR MOD decreased to a low of
0.11 on day 4 and remained low at 0.15 to 0.17 on days
12 through 120 after castration. Recurrent CWR22 tumors
obtained 150 days after castration exhibited lower per-
cent AR positivity (72.1  7.6%) than CWR22 tumors from
intact, androgen-stimulated mice (P  0.03). However,
among malignant nuclei expressing AR, MOD was similar
(P  0.99) in the original CWR22 under androgen stim-
ulation and recurrent CWR22 in the absence of testicular
androgens. Immunostaining of CWR22 tumors before
and after castration yielded similar results when the poly-
clonal antibodies AR-52 and PG-21 were used instead of
AR mAb F39.4.1 (data not shown). Western blotting (Fig-
ure 2) of CWR22 tumor lysates revealed similar AR levels
in androgen-dependent and recurrent CWR22 tumors
and reduced AR levels after castration until tumor recur-
rence.
The number of cells expressing Ki-67 in CWR22 tu-
mors before and after castration were summarized in
Table 1. Ki-67 positivity was high in CWR22 tumors from
intact nude mice (Figure 1), decreased gradually on days
1 to 4 after castration, and remained at low or undetect-
able levels on day 6 through day 90 after castration.
Although most CWR22 cells were in growth arrest, prolif-
erating cells occurred randomly at a frequency 1%
beyond day 6 until day 120 when multiple foci of 5 to 20
proliferating cells were detected throughout the tumors
(Figure 1). Recurrent CWR22 tumors, compared to the
original CWR22 tumors, exhibited lower cellular prolifer-
ation (49.1  7.4%, P  0.006). Mean serum PSA levels
(261.5  123.0 ng/ml) of mice bearing recurrent tumors
(n  6) increased to levels similar to those of tumor
bearing intact mice (246.7  55.3 ng/ml) (Table 1).
Foci of recurrent cellular proliferation, as indicated by
Ki-67 staining, appeared on day 120 day after castration.
When these proliferating foci were immunostained for
PSA expression using double-staining immunohisto-
chemistry, positive cytoplasmic staining for PSA was ob-
served in the foci that contained Ki-67-positive cells (Fig-
ure 3). Moreover, the appearance of proliferating cells on
day 120 after castration was associated with increased
(P  0.01) serum PSA levels (24  3 ng/ml) compared to
day 90 after castration (11  2 ng/ml).
Recurrent CWR22 tumors showed more heteroge-
neous AR positivity, AR MOD, and Ki-67 positivity (Figure
4; A, B, and C) than CWR22 tumors from intact mice
before castration (F-tests; P  0.001, 0.05, and 0.05,
respectively). Intertumor heterogeneity of cellular prolif-
eration in recurrent CWR22 was reflected in serum PSA
levels that ranged from 25 to 740 ng/ml when measured
in recurrent tumor-bearing mice. Throughout the study
period, AR MOD showed a parallel trend with Ki-67 pos-
itivity (r  0.64, P  0.03) and PSA levels (r  0.77, P 
0.02) (Table 1). In addition, Ki-67 positivity was highly
correlated with PSA levels (r  0.90, P  0.002).
Table 1. Quantitation of Tumor Volume (cm3), AR Expression (AR MOD and %AR Positivity), Tumor Cellular Proliferation (%Ki-
67 Positivity), and PSA Serum Levels (ng/ml) and Tissue Expression (%PSA Positivity) Measured in Androgen-Stimulated,













intact CWR22 12 1.11  0.94† 0.26  0.01‡ 98.5  0.2 73.5  4.4 246.7  55.3† 17.4  3.6
Day 1 2 0.15  0.10 28.5  7.4 56.9  7.5 3.4  1.0
Day 2 4 0.81  0.09 0.16  0.08 2.3  5.5 26.1  5.6 169.0  53.7 5.5  2.8
Day 4 2 0.11  0.09 9.9  8.6 9.4  8.1 4.8  1.1
Day 6 6 0.72  0.49 0.15  0.06 62.7  4.8§ 0.8  0.5 109.9  76.3 5.6  1.5
Day 12 6 0.81  0.27 0.17  0.06 70.9  4.9§ 0.3  0.3 18.8  10.8 0.8  0.9
Day 32 4 0.64  0.25 0.17  0.11 70.4  7.3§ 0.1  0.3 5.6  4.1 0.6  0.3
Day 64 2 0.15  0.05 71.7  12.2§ 0.4  0.2 1.1  0.1
Day 90 4 0.64  0.30 0.17  0.05 73.4  6.5§ 0.8  0.5 11.1  1.8 1.5  0.7
Day 120 4 0.78  0.37 0.17  0.03 72.3  8.4§ 3.3  1.2 21.3  4.1 3.4  0.1
Recurrent CWR22 12 1.63  0.38 0.26  0.01¶ 72.1  7.6§ 49.1  7.4¶ 261.5  123.0¶ 7.2  1.3¶
*AR mean optical density (MOD), percent AR positivity, percent Ki-67 positivity, serum PSA level, and percent PSA positivity at all time points after
castration decreased significantly (P  0.01) compared to intact CWR22 except no significant differences were found for AR MOD in recurrent CWR22
and percent AR positivity on days 90 and 120 after castration compared to day 0 (P  0.05).
†Tumor volume and serum PSA is described by mean  SD and therefore the data for time points containing only two measurements were not
presented.
‡The image analysis data for all nuclei for all tumors at each time point is described by mean  SD. Each tumor is represented by 20 images
containing 200 to 250 nuclei for AR and 400 to 500 nuclei for Ki-67.
§Percent AR positivity on days 6, 12, 32, 64, 90, and 120 after castration and upon recurrence increased significantly (P  0.001) compared to
days 1, 2, and 4 after castration.
¶Recurrent CWR22 showed a significant increase in AR MOD, percent Ki-67 positivity, serum PSA level, and percent PSA positivity compared to
time points after castration (P  0.01).
Serum PSA level and percent PSA positivity on day 120 after castration were significantly higher than on day 90 after castration (P  0.05).
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Immunopositivity of PSA was highest in tumors from
intact mice, decreased after castration, and remained
low until sometime between 90 to 120 days after castra-
tion when an increase was noted within foci of proliferat-
ing cells. Immunopositivity of PSA was significantly cor-
related with AR MOD (r  0.658, P  0.028), Ki-67
positivity (r  0.773, P  0.006), and serum PSA levels
(r  0.818, P  0.014).
Discussion
In the present study, the temporal relationship between
AR expression and cellular proliferation was investigated
in CWR22 CaP xenografts during the transition from an-
drogen-dependent to recurrent growth. Reduced AR pro-
tein immunostaining in CWR22 tumors after castration
was similar to that observed in ventral prostates of cas-
trated rats and mice.5,26,27 However, on day 6 after cas-
tration, percent AR positivity increased several fold and
remained at higher levels on days 12, 32, 64, 90, and
120. Although AR was expressed in most nuclei, nuclear
AR staining (MOD) remained relatively low throughout the
period of tumor regression after castration. Proliferation of
tumor cells ceased by day 6 after castration and re-
mained at low to undetectable levels through day 90.
Thus, during the period of tumor remission after andro-
gen deprivation, nuclear AR levels were low and tumors
Figure 1. AR and Ki-67 immunohistochemistry of CWR22 tumors. AR ex-
pression was similar in androgen-dependent and recurrent tumors. AR-
positive cells decreased to a minimum on day 2 after castration. Nuclear
localization of AR returned on day 6 after castration but its intensity was
lower than in androgen-dependent tumors. Higher percentages of AR-posi-
tive cells with lower levels of AR-staining intensity were recognized on days
32, 64, 90, and 120 after castration. Left: AR immunohistochemistry (scale
bar, 10 m). A: CWR22 before castration. B: Day 2 after castration. C: Day 6
after castration. D: Day 120 after castration. E: Recurrent CWR22 150 days
after castration. MIB-1 detection of the Ki-67 nuclear proliferation antigen
showed similar rates of cellular proliferation in T-stimulated and recurrent
tumors. Proliferation decreased on day 2 after castration and reached a level
that was barely detectable on days 6 and 12 after castration. Proliferation was
detectable as small nests of Ki-67-positive cells on day 120 after castration.
Right: Ki-67 immunohistochemistry (scale bar, 20 m). F: CWR22 before
castration. G: Day 2 after castration. H: Day 6 after castration. I: Day 120 after
castration. J: Recurrent CWR22 150 days after castration.
Figure 2. Western immunoblot analysis of AR protein in CWR22 tumors. An
AR protein of 110 to 114 kd was present in lysates of androgen-dependent
CWR22 tumors from intact mice. AR protein decreased after castration until
tumor recurred 150 days after castration. AR protein levels found in recur-
rent tumors in the absence of androgens were similar to those found in the
original androgen-dependent tumors. The position of the molecular mass
marker (kd) is indicated. This experiment was performed with two to six
different tumors at each time point with similar results.
Figure 3. PSA and Ki-67 double immunohistochemistry of CWR22 tumors
harvested from a mouse on day 120 after castration. Tissue PSA expression
was visualized with diaminobenzidine tetrahydrochloride (cytoplasmic
brown staining, white arrows) and Ki-67 expression was visualized with
AEC (dark red nuclear staining, black arrows). Counterstaining was done
with hematoxylin. Proliferating tumor cells emerged from the same foci
where PSA was expressed (scale bar, 20 m). Ki-67 immunostaining from the
double immunohistochemistry showed a pattern of numerous blobs in the
nucleoplasm rather than a typical uniform nuclear staining. Protease treat-
ment during PSA immunohistochemistry may have degraded Ki-67 protein.
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remained quiescent. Agus and associates28 reported in
their studies of cell-cycle regulators in the CWR22 xeno-
graft that cellular proliferation assessed using Ki-67 and
visual scoring fell to very low levels by day 10 after
castration and remained so through day 30 after castra-
tion. The percentage of cells that stained intensely with
AR mAb (F39.4.1) was low (10%) on days 3, 5, 7, and 10
after castration and reached the level of intact tumors by
day 25 and thereafter. The difference between their and
our reports may result from their dependence on visual
scoring of AR immunostaining or their use of higher con-
centrations of AR mAb (2 g/ml) that may have increased
nonspecific staining.20
In recurrent tumors 150 days after castration, AR ex-
pression and cellular proliferation were more heteroge-
neous than in tumors from intact mice; recurrent tumors
exhibited lower percent-positive nuclei and greater vari-
ation between tumors than CWR22 tumors from intact
mice. However, among nuclei immunostained for AR,
there was no difference in AR MOD between intact and
recurrent tumors. Previous studies have established that
AR activation subsequent to binding of androgen results
in increased nuclear levels of AR,29 homodimerization of
AR,30 and binding of AR to DNA sequences that function
as enhancers for AR-induced transcriptional activa-
tion.1,2,31 The similar levels of AR expression in intact and
recurrent tumors suggests that nuclear AR may be sta-
bilized despite the absence of testicular androgen in
recurrent CWR22 by a ligand-independent or synergistic
mechanism. AR activation is linked closely to stabilization
of AR protein; binding of androgen stabilizes AR causing
it to have a slower rate of degradation.32 AR MOD, by its
definition, represents a mean nuclear staining intensity
relative to cytoplasm.20 Therefore, increased AR MOD
may reflect AR activation. Another possible mechanism
of increased AR expression in recurrent CWR22 is AR
gene amplification. AR gene amplification was detected
in 7 of 23 cases of recurrent human CaP whereas none
was detected before androgen-deprivation therapy.33
However, AR gene amplification in recurrent CWR22 tu-
mors was not detected using Southern blot analysis and
competitive reverse transcriptase-polymerase chain re-
action.34
Because AR was expressed in a lower percentage of
cells and at a lower MOD in those cells expressing AR on
days 1 to 4 after castration and AR re-expression oc-
curred on gross tumor recurrence, the temporal relation-
ship between recovery of AR expression and the onset of
cellular proliferation should provide insight into the role of
AR in CaP recurrence after castration. On day 120 after
castration, when recurrent tumor growth was indicated by
increased serum PSA but tumor sites did not yet demon-
strate growth grossly, small foci of tumor cells were rec-
ognized in harvested samples that immunostained for
Ki-67 and expressed PSA. These findings suggested
these foci were precursors of the recurrent CWR22 tumor
that appears grossly 150 days after castration. Two
groups of investigators have reported on the relationship
between serum PSA and tumor recurrence after castra-
tion in the CWR22 model. Serum PSA increase before
gross tumor recurrence in the CWR22 model was re-
ported first by Nagabhushan and associates.12 The time
course of these events cannot be compared to our results
because they performed castration at higher tumor vol-
umes. Agus and associates28 castrated CWR22 tumor-
bearing mice at tumor volumes similar to our studies.
They reported increased serum PSA 115 days after
castration that preceded tumor recurrence recognized
grossly 20 days later. We reported previously that PSA
is one of several known androgen-regulated genes
whose mRNA was expressed at increased levels in re-
current CWR22 despite the absence of testicular andro-
gen.3 In the current study, these RNA findings were con-
firmed by PSA protein quantitation at the tissue level. PSA
is a well known androgen-regulated gene,35,36 however,
other factors such as vitamin D37 and transforming
growth factor-138 have been shown to be involved in
transcriptional regulation of the PSA gene. One or more of
Figure 4. Comparison of heterogeneity of AR expression and Ki-67 expres-
sion in CWR22 specimens from intact mice and on recurrence 150 days
after castration. A: Mean percent AR positivity. B: MOD of AR. C: Mean
percent Ki-67 positivity.
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these same factors may also be an initiator of recurrent
growth. Nonetheless, coincidental increased PSA serum
levels and tissue expression and the recurrence of tumor
cellular proliferation might be caused by the same mech-
anisms, one of which is reactivation of AR.
Understanding the mechanisms driving recurrent
growth is one of the most important issues in CaP re-
search.39–41 Because AR is a growth-stimulating tran-
scription factor in CaP, reactivation of AR in the absence
of testicular androgen could be one of the molecular
events that initiates cellular proliferation and leads to
tumor recurrence. Several mechanisms have been pro-
posed for activation of AR in the absence of testicular
androgen. AR mutations that alter ligand specificity may
influence tumor progression subsequent to androgen de-
privation by making AR more responsive to adrenal an-
drogens. CWR22 cells express a mutant AR (His 874 to
Tyr) that has normal transcriptional activity in response to
testosterone and dihydrotestosterone but has altered li-
gand specificity making it more sensitive to activation by
adrenal androgens including dehydroepiandrosterone.13
Alternatively, a ligand-independent mechanism might
cause transcriptional activation of AR. Protein kinase A
and C modulators might activate AR in the absence of
ligand by altering phosphorylation of AR42–45 or AR co-
activators.46,47 Stimulation of PKA activity resulted in ac-
tivation of the N-terminal domain of AR in LNCaP cells.48
Transfected AR was reported to be activated by insulin-
like growth factor I, epidermal growth factor, and keratin-
ocyte growth factor in DU-145 cells and PSA was in-
creased by insulin-like growth factor I in LNCaP cells.49
Overexpression of HER-2/neu receptor tyrosine kinase
was reported to increase expression of PSA and enhance
growth in the androgen-dependent human CaP LAPC-4
xenograft.50 These effects required AR expression and
seemed to occur through cross-talk between the AR and
HER-2/neu pathways. We reported recently that high-
level expression, increased stability, and nuclear local-
ization of AR in recurrent tumor cells were associated with
increased sensitivity to the growth-promoting effects of
dihydrotestosterone at concentrations as low as the fem-
tomolar range.34 Additionally, we have shown that high
expression of transcriptional intermediary factor 2 and
steroid receptor coactivator 1 in recurrent CaP increases
AR transactivation in response to physiological concen-
trations of adrenal androgens or other steroids with affin-
ity for AR.51 A single event or combination of events that
affect AR function may lead to recurrent tumor growth in
the absence of testicular androgen.
The re-expression of AR and known androgen-regu-
lated genes in the 150-day recurrent CWR223,14,15 sug-
gests that AR reactivation has a role in stimulating recur-
rent tumor growth. AR MOD decreased after castration
and failed to increase until sometime between 120 days
after castration and gross tumor recurrence. At the 120-
day time point, if proliferating cells exhibited increased
AR MOD, their rarity would preclude detection because
5% of malignant cells were proliferating. Quantitation of
antigens using double-staining immunohistochemistry is
technically difficult; our attempts to measure AR expres-
sion in Ki-67-immunopositive versus immunonegative
cells have been unsuccessful thus far. However, if the small
foci of tumor cells on day 120 after castration are precursors
of recurrent tumors, direct comparison of AR, androgen-
regulated gene products, and other molecules in these foci
of cellular proliferation versus other regions of the tumor may
be useful to evaluate specific mechanisms driving recurrent
growth. Further study of this transition from androgen-de-
pendent to androgen-independent growth in CWR22 may
provide valuable insights into the mechanism of androgen-
deprivation treatment failure in patients.
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